Clinical Trial Update: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) [Phase 3]

View source ↗

Summary

Clinical trial update for a Phase 3 open-label extension (MAESTRO-NAFLD-OLE) of resmetirom (MGL-3196) in non-alcoholic fatty liver disease, focusing on safety a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Resmetirom (resmetirom)

Snippet

Sponsor: Madrigal Pharmaceuticals, Inc. | Conditions: Non-Alcoholic Fatty Liver Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING